Solventum Q1 sales down 3% reported but up 2.1% organically; affirms 2026 growth and EPS guidance

Solventum reported a 3.0% decline in reported sales to $2.0 billion for Q1 2026, but organic sales grew 2.1%, driven by volume and product mix improvements. Adjusted earnings per share rose 10.6% to $1.48, despite GAAP EPS falling to $0.07 due to separation and restructuring costs. The company affirmed its full-year 2026 guidance, expecting organic sales growth of 2-3% and adjusted EPS near the high end of $6.40 to $6.60. Free cash flow was negative at $273 million, impacted by separation activities and seasonality. Solventum continues to invest in R&D and manufacturing capacity to support future growth.